ScreenerHero

DMRA Damora Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · damoratx.com
20.56USD+1.58%Mkt Cap: 1.27B $P/E: —

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclona…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap1.27B USD
Enterprise Value839.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-209.84M USD
Revenue/Share—
Last Price20.56 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.46
PEG—
EV/EBITDA-8.71
EV/Revenue—
P/S—
P/B3.29
EPS (TTM)-0.25
EPS (Forward)-2.17
52W Range
3.50049% of range38.33
52W High38.33 USD
52W Low3.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.29%
ROA-80.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.73M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.26%
Net Debt-540.52M USD
Net Debt/EBITDA5.61
Balance Sheet
Debt/Equity0.00
Current Ratio19.73
Quick Ratio19.65
Book Value/Sh6.25 USD
Cash/Share8.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 30, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)46.89 USD
Upside (mean)+128.1%
Target Range40.00 USD – 60.00 USD
40.00+128.1% to mean60.00
# Analysts9
Ownership
Shares Out.61.74M
Float40.89M
Insiders8.43%
Institutions105.78%
Short Interest
Short Ratio10.9d
Short % Float8.95%
Short % Out.7.67%
Shares Short4.73M
Short (prev mo.)4.74M
Technical
SMA 5026.84 (-23.4%)
SMA 20026.02 (-21.0%)
Beta1.44
S&P 52W Chg15.84%
Avg Vol (30d)639.24K
Avg Vol (10d)702.53K
Technical Indicators
RSI (14)35.9
MACD-2.1007
MACD Signal-2.1455
MACD Hist.+0.0448
BB Upper28.11 USD
BB Middle22.39 USD
BB Lower16.66 USD
BB Width51.19%
ATR (14)1.695 USD
Vol Ratio (20d)0.42x